Karl-Günter Technau1, Renate Strehlau1, Faeezah Patel1, Stephanie Shiau1, Megan Burke1, Martie Conradie1, Gillian Sorour1, Gayle G Sherman2, Ashraf Coovadia1, Pamela M Murnane3, Elaine J Abrams4, Louise Kuhn5. 1. Empilweni Services and Research Unit, Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa. 2. Empilweni Services and Research Unit, Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa; Centre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases, Johannesburg, South Africa. 3. Empilweni Services and Research Unit, Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa; Gertrude H Sergievsky Center, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Center for AIDS Prevention Studies, Department of Medicine, University of California San Francisco, CA, USA. 4. Empilweni Services and Research Unit, Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa; ICAP at Columbia, Mailman School of Public Health, and Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA. 5. Empilweni Services and Research Unit, Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa; Gertrude H Sergievsky Center, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: lk24@columbia.edu.
Abstract
BACKGROUND: Initiation of antiretroviral therapy (ART) following diagnosis of HIV infection at birth is an emerging area of paediatric HIV care. We present outcomes of HIV-infected infants identified at birth at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa. METHODS: From September, 2013 (era 1), only high-risk HIV-exposed infants were offered diagnostic HIV PCR tests at birth. From June, 2014 (era 2), all HIV-exposed infants were offered laboratory-based diagnostic PCR tests. From October, 2014 (era 3), point of care (POC) diagnostic PCR tests were also done if staff availability allowed. We describe time to ART initiation, mortality, retention in care, and viral suppression among the HIV-infected infants identified across these eras. FINDINGS: We tested 5449 HIV-exposed infants who were born between Sept 1, 2013, and June 30, 2016. 88 neonates with confirmed HIV infection were identified and included in the study, of which 86 (98%) started ART. Median age at ART initiation decreased from 9 days (IQR 6-25) in eras 1 and 2 to 2 days (1-8) in era 3. In era 3, more neonates who were co-tested with POC testing started ART within 48 h of birth (29 [83%] of 35; median 1 day [IQR 1-2]) than infants who were not co-tested (one [4%] of 29; median 6 days [5-10]). The probability of mortality by 12 months across the eras was 14% (95% CI 8-24) and did not differ by era. Of the 72 infants who survived and initiated ART at the site, 56 (78%) were retained at 12 months. Of the 56 infants retained in care, 40 (71%) had a viral load less than 400 copies per mL at 12 months, with no differences between eras (p=0·23). INTERPRETATION: HIV-infected infants can be identified at birth and ART can be initiated within hours to days. Although most infants in our cohort started ART, mortality remained unacceptably high with suboptimal retention and viral suppression. Reducing mortality and improving retention and viral suppression remain urgent priorities. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institute of Allergy and Infectious Disease, National Institutes of Health, USAID/PEPfAR, and the South African National HIV Programme.
BACKGROUND: Initiation of antiretroviral therapy (ART) following diagnosis of HIV infection at birth is an emerging area of paediatric HIV care. We present outcomes of HIV-infected infants identified at birth at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa. METHODS: From September, 2013 (era 1), only high-risk HIV-exposed infants were offered diagnostic HIV PCR tests at birth. From June, 2014 (era 2), all HIV-exposed infants were offered laboratory-based diagnostic PCR tests. From October, 2014 (era 3), point of care (POC) diagnostic PCR tests were also done if staff availability allowed. We describe time to ART initiation, mortality, retention in care, and viral suppression among the HIV-infected infants identified across these eras. FINDINGS: We tested 5449 HIV-exposed infants who were born between Sept 1, 2013, and June 30, 2016. 88 neonates with confirmed HIV infection were identified and included in the study, of which 86 (98%) started ART. Median age at ART initiation decreased from 9 days (IQR 6-25) in eras 1 and 2 to 2 days (1-8) in era 3. In era 3, more neonates who were co-tested with POC testing started ART within 48 h of birth (29 [83%] of 35; median 1 day [IQR 1-2]) than infants who were not co-tested (one [4%] of 29; median 6 days [5-10]). The probability of mortality by 12 months across the eras was 14% (95% CI 8-24) and did not differ by era. Of the 72 infants who survived and initiated ART at the site, 56 (78%) were retained at 12 months. Of the 56 infants retained in care, 40 (71%) had a viral load less than 400 copies per mL at 12 months, with no differences between eras (p=0·23). INTERPRETATION:HIV-infected infants can be identified at birth and ART can be initiated within hours to days. Although most infants in our cohort started ART, mortality remained unacceptably high with suboptimal retention and viral suppression. Reducing mortality and improving retention and viral suppression remain urgent priorities. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institute of Allergy and Infectious Disease, National Institutes of Health, USAID/PEPfAR, and the South African National HIV Programme.
Authors: P E Palumbo; C Raskino; S Fiscus; S Pahwa; M G Fowler; S A Spector; J A Englund; C J Baker Journal: JAMA Date: 1998-03-11 Impact factor: 56.272
Authors: Lisa Frigati; Elke Wynberg; Jean Maritz; Sandi Holgate; Mark F Cotton; Helena Rabie Journal: Pediatr Infect Dis J Date: 2017-06 Impact factor: 2.129
Authors: E J Abrams; J Weedon; R W Steketee; G Lambert; M Bamji; T Brown; M L Kalish; E E Schoenbaum; P A Thomas; D M Thea Journal: J Infect Dis Date: 1998-07 Impact factor: 5.226
Authors: Louise Kuhn; Gillian Hunt; Karl-Günter Technau; Ashraf Coovadia; Johanna Ledwaba; Sam Pickerill; Martina Penazzato; Silvia Bertagnolio; Claude A Mellins; Vivian Black; Lynn Morris; Elaine J Abrams Journal: AIDS Date: 2014-07-17 Impact factor: 4.177
Authors: Victoria Iyun; Karl-Gunter Technau; Brian Eley; Helena Rabie; Andrew Boulle; Geoffrey Fatti; Matthias Egger; Frank Tanser; Robin Wood; Lee Fairlie; Mark F Cotton; Mary-Ann Davies Journal: Pediatr Infect Dis J Date: 2020-02 Impact factor: 3.806
Authors: Ciputra Adijaya Hartana; Pilar Garcia-Broncano; Yelizaveta Rassadkina; Xiaodong Lian; Chenyang Jiang; Kevin B Einkauf; Kenneth Maswabi; Gbolahan Ajibola; Sikhulile Moyo; Terence Mohammed; Comfort Maphorisa; Joseph Makhema; Yuko Yuki; Maureen Martin; Kara Bennett; Patrick Jean-Philippe; Mathias Viard; Michael D Hughes; Kathleen M Powis; Mary Carrington; Shahin Lockman; Ce Gao; Xu G Yu; Daniel R Kuritzkes; Roger Shapiro; Mathias Lichterfeld Journal: Cell Rep Date: 2022-07-19 Impact factor: 9.995
Authors: Jane R Millar; Isabella Fatti; Noxolo Mchunu; Nomonde Bengu; Nicholas E Grayson; Emily Adland; David Bonsall; Moherndran Archary; Philippa C Matthews; Thumbi Ndung'u; Philip Goulder Journal: AIDS Date: 2021-08-01 Impact factor: 4.632
Authors: Jane R Millar; Nomonde Bengu; Rowena Fillis; Ken Sprenger; Vuyokazi Ntlantsana; Vinicius A Vieira; Nisreen Khambati; Moherndran Archary; Maximilian Muenchhoff; Andreas Groll; Nicholas Grayson; John Adamson; Katya Govender; Krista Dong; Photini Kiepiela; Bruce D Walker; David Bonsall; Thomas Connor; Matthew J Bull; Nelisiwe Nxele; Julia Roider; Nasreen Ismail; Emily Adland; Maria C Puertas; Javier Martinez-Picado; Philippa C Matthews; Thumbi Ndung'u; Philip Goulder Journal: EClinicalMedicine Date: 2020-05-08
Authors: Emily Adland; Jane Millar; Nomonde Bengu; Maximilian Muenchhoff; Rowena Fillis; Kenneth Sprenger; Vuyokasi Ntlantsana; Julia Roider; Vinicius Vieira; Katya Govender; John Adamson; Nelisiwe Nxele; Christina Ochsenbauer; John Kappes; Luisa Mori; Jeroen van Lobenstein; Yeney Graza; Kogielambal Chinniah; Constant Kapongo; Roopesh Bhoola; Malini Krishna; Philippa C Matthews; Ruth Penya Poderos; Marta Colomer Lluch; Maria C Puertas; Julia G Prado; Neil McKerrow; Moherndran Archary; Thumbi Ndung'u; Andreas Groll; Pieter Jooste; Javier Martinez-Picado; Marcus Altfeld; Philip Goulder Journal: Nat Commun Date: 2020-04-14 Impact factor: 14.919